+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

  • ID: 4911702
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 77 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Cinnagen Co
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • MORE
Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

Summary

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 15 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3, 5 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Age Related Macular Degeneration, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinopathy, Retinopathy Of Prematurity and Uveal Melanoma.

The latest report Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Cinnagen Co
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • MORE
  • Introduction
  • Report Coverage
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Cinnagen Co
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Shandong Boan Biological Technology Co Ltd
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
  • aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BB-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSL-346 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ziv-aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ziv-aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Alteogen Inc, H1 2020
  • Pipeline by Benitec Biopharma Ltd, H1 2020
  • Pipeline by Cinnagen Co, H1 2020
  • Pipeline by Coherus BioSciences Inc, H1 2020
  • Pipeline by CSL Ltd, H1 2020
  • Pipeline by Formycon AG, H1 2020
  • Pipeline by Gene Techno Science Co Ltd, H1 2020
  • Pipeline by Huons Global Co Ltd, H1 2020
  • Pipeline by Luye Pharma Group Ltd, H1 2020
  • Pipeline by Momenta Pharmaceuticals Inc, H1 2020
  • Pipeline by PharmAbcine Inc, H1 2020
  • Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Pipeline by Samsung Bioepis Co Ltd, H1 2020
  • Pipeline by Shandong Boan Biological Technology Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Cinnagen Co
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Shandong Boan Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll